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Abstract
Following an application from Specialised Nutrition Europe (formerly IDACE), submitted for
authorisation of a health claim pursuant to Article 14 of Regulation (EC) No 1924/2006 via the
Competent Authority of France, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was
asked to deliver an opinion on the scientiﬁc substantiation of a health claim related to vitamin C and
protection of DNA, proteins and lipids from oxidative damage. The Panel considers that vitamin C is
sufﬁciently characterised and that protection of DNA, proteins and lipids from oxidative damage is a
beneﬁcial physiological effect. The target population proposed by the applicant is infants (from birth)
and young children up to 3 years of age. The Panel has previously assessed a claim on vitamin C and
protection of DNA, proteins and lipids from oxidative damage with a favourable outcome. The target
population was the general population. The Panel considers that the role of vitamin C in protection of
DNA, proteins and lipids from oxidative damage applies to all ages, including infants and young
children up to 3 years of age. The Panel concludes that a cause and effect relationship has been
established between the dietary intake of vitamin C and protection of DNA, proteins and lipids from
oxidative damage.
© 2017 European Food Safety Authority. EFSA Journal published by John Wiley and Sons Ltd on behalf
of European Food Safety Authority.
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Summary
Following an application from Specialised Nutrition Europe (SNE, formerly IDACE), submitted for
authorisation of a health claim pursuant to Article 14 of Regulation (EC) No 1924/2006 via the
Competent Authority of France, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was
asked to deliver an opinion on the scientiﬁc substantiation of a health claim related to vitamin C and
protection of DNA, proteins and lipids from oxidative damage.
The scope of the application was proposed to fall under a health claim referring to children’s
development and health.
The general approach of the NDA Panel for the evaluation of health claims applications is outlined
in the EFSA general guidance for stakeholders on health claim applications and the guidance on the
scientiﬁc requirements for health claims related to antioxidants, oxidative damage and cardiovascular
health.
The food constituent that is the subject of the health claim is vitamin C, which is an essential
nutrient and can be measured in foods by established methods. The Panel considers that vitamin C is
sufﬁciently characterised.
The claimed effect proposed by the applicant is ‘protection of cells due to its antioxidant activity’.
The target population proposed by the applicant is infants (from birth) and young children up to
3 years of age. The Panel considers that protection of DNA, proteins and lipids from oxidative damage
is a beneﬁcial physiological effect.
The Panel has previously assessed a claim on vitamin C and protection of DNA, proteins and lipids
from oxidative damage with a favourable outcome. The target population was the general population.
The Panel considers that the role of vitamin C in protection of DNA, proteins and lipids from oxidative
damage applies to all ages, including infants and young children up to 3 years of age.
The Panel concludes that a cause and effect relationship has been established between the dietary
intake of vitamin C and protection of DNA, proteins and lipids from oxidative damage.
The following wording reﬂects the scientiﬁc evidence: ‘Vitamin C contributes to the protection of
cell constituents from oxidative damage’.
Vitamin C and protection from oxidative damage
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1. Introduction
1.1. Background and Terms of Reference as provided by the requestor
Regulation (EC) No 1924/20061 harmonises the provisions that relate to nutrition and health claims,
and establishes rules governing the Community authorisation of health claims made on foods. As a
rule, health claims are prohibited unless they comply with the general and speciﬁc requirements of this
Regulation, are authorised in accordance with this Regulation, and are included in the lists of
authorised claims provided for in Articles 13 and 14 thereof. In particular, Articles 14–17 of this
Regulation lay down provisions for the authorisation and subsequent inclusion of reduction in disease
risk claims and claims referring to children’s development and health in a Community list of permitted
claims.
According to this Regulation, an application shall be submitted by the applicant to the national
competent authority of a Member State, which will make the application and any supplementary
information supplied by the applicant available to the European Food Safety Authority (EFSA).
1.2. Interpretation of the Terms of Reference
EFSA is requested to evaluate the scientiﬁc data submitted by the applicant in accordance with
Article 16 of Regulation (EC) No 1924/2006. On the basis of that evaluation, EFSA will issue an opinion
on the scientiﬁc substantiation of a health claim related to: vitamin C and protection of DNA, proteins
and lipids from oxidative damage.
The present opinion does not constitute, and cannot be construed as, an authorisation for the
marketing of vitamin C, a positive assessment of its safety, nor a decision on whether vitamin C is, or
is not, classiﬁed as a foodstuff. It should be noted that such an assessment is not foreseen in the
framework of Regulation (EC) No 1924/2006.
It should also be highlighted that the scope, the proposed wording of the claim, and the conditions
of use as proposed by the applicant may be subject to changes, pending the outcome of the
authorisation procedure foreseen in Article 17 of Regulation (EC) No 1924/2006.
1.3. Additional information
A health claim on vitamin C and protection of DNA, proteins and lipids from oxidative damage has
already been assessed by the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) with a
favourable outcome (EFSA NDA Panel, 2009).
2. Data and methodologies
2.1. Data
2.1.1. Information provided by the applicant
2.1.1.1. Food/constituent as stated by the applicant
According to the applicant, the food constituent that is the subject of the claim is vitamin C.
2.1.1.2. Health relationship as claimed by the applicant
According to the applicant, vitamin C ‘protects cells due to its antioxidant activity’.
The applicant stated that vitamin C is an essential nutrient and a key element for the metabolism of
almost all living organisms. An appropriate intake of vitamin C protects cells and DNA from oxidative
damage.
2.1.1.3. Wording of the health claim as proposed by the applicant
The applicant has proposed the following wording for the health claim: ‘Vitamin C protects cells due
to its antioxidant activity’. The alternative wordings are ‘ascorbic acid supports healthy cells by
scavenging free radicals’.
1 Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and health
claims made on foods. OJ L 404, 30.12.2006, p. 9–25.
Vitamin C and protection from oxidative damage
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2.1.1.4. Speciﬁc conditions of use as proposed by the applicant
The target population proposed by the applicant is infants and young children from birth to 3 years
of age.
According to the applicant, the quantities needed to achieve the claimed effects are as follows:
• For follow-on formulae, the content of vitamin C should be within the range set in Directive
2006/141/EC.
• For Foods for Special Medical Purposes, the content of vitamin C should be within the range
set in Directive 1999/21/EC, except if this is contrary to the intended use of the product.
• For processed cereal-based foods and other foods regulated by Directive 2006/125/EC
(as amended), a maximum vitamin C content should not exceed 12.5 mg/100 kcal
(25 mg/100 kcal for products fortiﬁed with vitamin C).
• For the other foods intended for infants and young children, the content in vitamin C should
not exceed 15% of the Nutrient Reference Values set in Directive 2006/141/EC, i.e. 15% of
30 mg/100 mL product ready for use.
2.1.2. Data provided by the applicant
Health claim application on vitamin C and protection of cells from oxidative damage pursuant to
Article 14 of Regulation 1924/2006 was presented in a common and structured format as outlined in
the Scientiﬁc and technical guidance for the preparation and presentation of applications for
authorisation of health claims (EFSA NDA Panel, 2011a).
As outlined in the General guidance for stakeholders on health claim applications, it is the
responsibility of the applicant to provide the totality of the available evidence (EFSA NDA Panel, 2016).
2.2. Methodologies
The general approach of the NDA Panel for the evaluation of health claim applications is outlined in
the EFSA general guidance for stakeholders on health claim applications (EFSA NDA Panel, 2016).
The scientiﬁc requirements for health claims related to antioxidants, oxidative damage and
cardiovascular health are outlined in a speciﬁc EFSA guidance (EFSA NDA Panel, 2011b).
3. Assessment
3.1. Characterisation of the food/constituent
The food constituent that is the subject of the health claims is vitamin C (L-ascorbic acid,
ascorbate), which is an essential nutrient and can be measured in foods by established methods.
Vitamin C is authorised for addition to foods (Annex I of Regulation (EC) No 1925/2006, Annex I of
Directive 2002/46/EC, Annex III of Directive 2006/141/EC, Annex IV of Directive 2006/125/EC and
Directive 2001/15/EC). This evaluation applies to vitamin C naturally present in foods and those forms
authorised for addition to foods (Annex II of Regulation (EC) No 1925/2006, Annex II of Directive
2002/46/EC, Annex III of Directive 2006/141/EC, Annex IV of Directive 2006/125/EC and Directive
2001/15/EC).
The Panel considers that the food constituent, vitamin C, which is the subject of the health claim, is
sufﬁciently characterised.
3.2. Relevance of the claimed effect to human health
The claimed effect proposed by the applicant is ‘protection of cells due to its antioxidant activity’.
The target population proposed by the applicant is infants (from birth) and young children up to
3 years of age.
From the information provided, the Panel notes that the claimed effect refers to protection of DNA,
proteins and lipids from oxidative damage.
The Panel considers that protection of DNA, proteins and lipids from oxidative damage is a
beneﬁcial physiological effect.
Vitamin C and protection from oxidative damage
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3.3. Scientiﬁc substantiation of the claimed effect
The Panel has previously assessed a claim on vitamin C and protection of DNA, proteins and lipids
from oxidative damage with a favourable outcome (EFSA NDA Panel, 2009). The target population was
the general population. The Panel considered that vitamin C plays a role in protection of DNA, proteins
and lipids from oxidative damage.
Vitamin C acts physiologically as a water-soluble antioxidant and plays a major role as a free
radical scavenger (Sadler et al., 1999; IoM, 2000). Vitamin C is part of the antioxidant defence system,
which is a complex network including endogenous antioxidants and dietary antioxidants, antioxidant
enzymes and repair mechanisms, with mutual interactions and synergetic effects among the various
components.
The Panel considers that the role of vitamin C in protection of DNA, proteins and lipids from oxidative
damage applies to all ages, including infants and young children (from birth to 3 years of age).
The Panel concludes that a cause and effect relationship has been established between the dietary
intake of vitamin C and protection of DNA, proteins and lipids from oxidative damage.
3.4. Panel’s comments on the proposed wording
The Panel considers that the following wording reﬂects the scientiﬁc evidence: ‘Vitamin C
contributes to the protection of cell constituents from oxidative damage’.
3.5. Conditions and restrictions of use
The Panel considers that in order to bear the claim:
• Follow-on formulae should comply with the criteria for the composition of follow-on formulae
as laid down in Directive 2006/141/EC.
• Nutritionally complete foods for special medical purposes intended for use by infants and
nutritionally complete foods for special medical purposes other than those intended for use by
infants should comply with the criteria for the composition of these foods as laid down in
Directive 1999/21/EC.
• Processed cereal-based foods for infants and young children should comply with the criteria for
the composition of these foods as laid down in Directive 2006/125/EC.
• Other foodstuffs intended for infants and young children should provide at least 15% of the
reference values for the nutritional labelling of foods intended for infants and young children as
laid down in Directive 2006/141/EC. Such amounts can easily be consumed as part of a
balanced diet. Dietary reference values for vitamin C have been set for infants and young
children (EFSA NDA Panel, 2013).
• The target population is infants and young children up to 3 years of age. EFSA did not set
tolerable upper intake level (UL) for vitamin C (EFSA, 2004).
4. Conclusions
On the basis of the data presented, the Panel concludes that:
• The food/constituent, vitamin C, which is the subject of the health claim, is sufﬁciently
characterised.
• The claimed effect proposed by the applicant is ‘protection of cells due to its antioxidant
activity’. The target population proposed by the applicant is infants and young children from
birth to 3 years of age. Protection of DNA, proteins and lipids from oxidative damage is a
beneﬁcial physiological effect.
• A cause and effect relationship has been established between the dietary intake of vitamin C
and protection of DNA, proteins and lipids from oxidative damage.
• The following wording reﬂects the scientiﬁc evidence: ‘Vitamin C contributes to the protection
of cell constituents from oxidative damage’.
• In order to bear the claim, follow-on formulae should comply with the criteria for the
composition of follow-on formulae as laid down in Directive 2006/141/EC; nutritionally
complete foods for special medical purposes intended for use by infants and nutritionally
complete foods for special medical purposes other than those intended for use by infants
should comply with the criteria for the composition of these foods as laid down in Directive
Vitamin C and protection from oxidative damage
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1999/21/EC; processed cereal-based foods for infants and young children should comply with
the criteria for the composition of these foods as laid down in Directive 2006/125/EC; and
other foodstuffs intended for infants and young children should provide at least 15% of the
reference values for the nutritional labelling of foods intended for infants and young children as
laid down in Directive 2006/141/EC. Such amounts can easily be consumed as part of a
balanced diet. The target population is infants and young children up to 3 years of age. The
UL for vitamin C is not established.
Steps taken by EFSA
1) Health claim application on vitamin C and protection of DNA, proteins and lipids from
oxidative damage pursuant to Article 14 of Regulation (EC) No 1924/2006 (Claim serial No:
0095_FR). Submitted by Specialised Nutrition Europe (SNE, formerly IDACE), 9-31 Avenue
des Nerviens, 1040 Brussels, Belgium.
2) This application was received by EFSA on 14/2/2008.
3) The scope of the application was proposed to fall under a health claim referring to children’s
development and health.
4) On 26/3/2008, during the validation process of the application, EFSA sent a request to the
applicant to provide missing information.
5) On 10/7/2016, EFSA received the missing information as submitted by the applicant.
6) The scientiﬁc evaluation procedure started on 07/9/2016.
7) During its meeting on 13/12/2016, the NDA Panel, having evaluated the data, adopted an
opinion on the scientiﬁc substantiation of a health claim related to vitamin C and protection
of DNA, proteins and lipids from oxidative damage.
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